[1] Brugts JJ,Boersma E,Chonchol M,Deckers JW,Bertrand M,Remme WJ .2007 .The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial. J Am Coll Cardiol, 50(22) : 2148-55.
[2] Mahmood IH,Abed MN,Merkhan MM .2012 .Effects of blocking of angiotensin system on the prevalenceof metabolic syndrome in type 2 diabetic patients. Pak J Med Sci, 29(1) : 140-3.
[3] Marusic-Vrsalovic M,Dominis M,Jaksic B,Kusec R .2003 .Angiotensin I-converting enzyme is expressed by erythropoietic cells of normal and myeloproliferative bone marrow. Br J Haematol, 123(3) : 539-41.
[4] Marathias K,Agroyannis B,Mavromoustakos T,Matsoukas J,Vlahakos D .2004 .Hematocrit-lowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Curr Top Med Chem, 4(4) : 483-6.
[5] Cheungpasitporn W,Thongprayoon C,Chiasakul T,Korpaisarn S,Erickson SB .2015 .Renin-angiotensin system inhibitors linked to anemia: a systematic review and metaanalysis. QJM, 108(11) : 879-84.
[6] Plata R,Cornejo A,Arratia C,Anabaya A,Perna A,Dimitrov BD .2002 .Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: A prospective randomised trial. Lancet, 359(9307) : 663-6.
[7] Winkelmayer WC,Kewalramani R,Rutstein M,Gabardi S,Vonvisger T,Chandraker A .2004 .Pharmacoepidemiology of anemia in kidney transplant recipients. J Am Soc Nephrol, 15(5) : 1347-52.
[8] Inoue A,Babazono T,Iwamoto Y. .2008 .Effects of the ReninAngiotensin system blockade on haemoglobin levels in type 2 diabetic patients with chronic kidney disease. Am J Hypertens, 21(3) : 317-22.
[9] Fountain JH,Lappin SL .2022 .Physiology, Renin Angiotensin System. StatPearls, : .
[10] Tetzner A,Gebolys K,Meinert C,Klein S,Uhlich A,Trebicka J .2016 .Phosphokinase A. Hypertension, 68(1) : 185-94.
[11] Patel VB,Zhong JC,Grant MB,Oudit GY .2016 .Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure. Circ Res, 118(8) : 1313-26.
[12] Donoghue M,Hsieh F,Baronas E,Godbout K,Gosselin M,Stagliano N,Communication A Novel Angiotensin-Converting N .2000 .. to Angiotensin 1-9. Circ Res, 87 : e1-9.
[13] Zhuo JL,Li XC .2011 .New insights and perspectives on intrarenal renin-angiotensin system: Focus on intracrine/intracellular angiotensin II. Peptides, 32(7) : 1551-65.
[14] Villapol S,Saavedra JM .2015 .Neuroprotective Effects of Angiotensin Receptor Blockers. Am J Hypertens, 28(3) : 289-99.
[15] Alnori H,Alassaf FA,Alfahad M,Qazzaz ME,Jasim M,Abed MN .2020 .Vitamin D and Immunoglobulin E Status in Allergic Rhinitis Patients Compared to Healthy People. J Med Life, 13(4) : 463-8.
[16] Yosypiv IV .2021 .Renin-angiotensin system in mammalian kidney development. Pediatr Nephrol, 36(3) : 479-89.
[17] Bagby SP,Lebard LS,Luo Z,Ogden BE,Corless C,Mcpherson ED .2002 .ANG II AT 1 and AT 2 receptors in developing kidney of normal microswine. Am J Physiol Ren Physiol, 283(4) : 755-64.
[18] Norwood VF,Craig MR,Harris JM,Gomez RA .1997 .Differential expression of angiotensin II receptors during early renal morphogenesis. Am J Physiol, 272(2 Pt 2) : R662-8.
[19] Schrankl J,Fuchs M,Broeker K,Daniel C,Kurtz A,Wagner C .2021 .Localization of angiotensin II type 1 receptor gene expression in rodent and human kidneys. Am J Physiol Renal Physiol, 320(4) : F644-53.
[20] Li XC,Zhuo JL .2016 .Recent Updates on the Proximal Tubule Renin-Angiotensin System in Angiotensin II-Dependent Hypertension. Curr Hypertens Rep, 18(8) : 63.
[21] Pei N,Mao Y,Wan P,Chen X,Li A,Chen H .2017 .Angiotensin II type 2 receptor promotes apoptosis and inhibits angiogenesis in bladder cancer. J Exp Clin Cancer Res, 36(1) : 77.
[22] de la Sierra .2006 .A. Angiotensin receptor blockers in hypertension and cardiovascular diseases. Cardiovasc Hematol Agents Med Chem, 4(1) : 67-73.
[23] Steckelings UM,Artuc M,Wollschläger T,Wiehstutz S,Henz BM .2001 .Angiotensin-converting enzyme inhibitors as inducers of adverse cutaneous reactions. Acta Derm Venereol, 81(5) : 321-5.
[24] Raimondo DDi,Tuttolomondo A,Buttà C,Miceli S,Licata G,Pinto A. .2012 .Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation. Curr Pharm Des, 18(28) : 4385-413.
[25] Benson SC,Pershadsingh HA,Ho CI,Chittiboyina A,Desai P,Pravenec M .2004 .Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ- modulating activity. Hypertension, 43(5) : 993-1002.
[26] Feig DI,Soletsky B,Johnson RJ .2008 .Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA, 300(8) : 924-32.
[27] Silveira KD,Coelho FM,Vieira AT,Barroso LC,Queiroz CM,Costa VV .2013 .Mechanisms of the anti-inflammatory actions of the angiotensin type1 receptor antagonist losartan in experimental models of arthritis. Peptides, 46 : 53-63.
[28] Mrug M,Stopka T,Julian BA,Prchal JF,Prchal JT .1997 .Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest, 100(9) : 2310.
[29] Kato H,Ishida J,Imagawa S,Saito T,Suzuki N,Matsuoka T .2005 .Enhanced erythropoiesis mediated by activation of the renin-angiotensin system via angiotensin II type 1a receptor. FASEB J, 19(14) : 2023-5.
[30] Doan TN,Gletsu N,Cole J,Bernstein KE .2001 .Genetic manipulation of the renin-angiotensin system. Curr Opin Nephrol Hypertens, 10(4) : 483-91.
[31] Naito M,Kawashima A,Akiba T,Takanashi M,Nihei H M .2003 .Effects of an angiotensin II receptor antagonist and angiotensinconverting enzyme inhibitors on burst forming units-erythroid in chronic hemodialysis patients. Am J Nephrol, 23(5) : 287-93.
[32] Jelkmann W. .2011 .Regulation of erythropoietin production. J Physiol, 589 : 1251.
[33] Nakamoto H,Kanno Y,Okada H,Suzuki H H .2004 .Erythropoietin resistance in patients on continuous ambulatory peritoneal dialysis. Adv Perit Dial, 20 : 111-6.
[34] Hu X,Li J,Fu M,Zhao X,Wang W. The JAK .2021 .STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther, 6(1) : 1-33.
[35] Yasuoka Y,Izumi Y,Fukuyama T,Inoue H,Oshima T,Yamazaki T .2021 .Effects of Angiotensin II on Erythropoietin Production in the Kidney and Liver. Molecules, 26(17) : 5399.
[36] Iriyama T,Wang W,Parchim NF,Song A,Blackwell SC,Sibai BM .2015 .Hypoxia-independent upregulation of placental hypoxia inducible factor-1α gene expression contributes to the pathogenesis of preeclampsia. Hypertension, 65(6) : 1307-15.
[37] An JN,Hwang JH,Lee JP,Chin HJ,Kim S,Kim DK .2015 .The Decrement of Haemoglobin Concentration with Angiotensin II Receptor Blocker Treatment Is Correlated with the Reduction of Albuminuria in Non-Diabetic Hypertensive Patients: PostHoc Analysis of ESPECIAL Trial. PLoS One, 10(6) : e0128632.
[38] Singer CE,Vasile CM,Popescu M,Popescu AIS,Marginean IC,Iacob GA .2023 .Role of Iron Deficiency in Heart FailureClinical and Treatment Approach: An Overview. , 13(2) : 304.
[39] Westenbrink BD,Visser FW,Voors AA,Smilde TDJ,Lipsic E,Navis G .2007 .Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J, 28(2) : 166-71.
[40] Jensen JD,Eiskjaer H,Bagger JP,Pedersen EB .1993 .Elevated level of erythropoietin in congestive heart failure relationship to renal perfusion and plasma renin. J Intern Med, 233(2) : 125-30.
[41] Kato H,Ishida J,Matsusaka T,Ishimaru T,Tanimoto K,Sugiyama F .2015 .Erythropoiesis and Blood Pressure Are Regulated via AT1 Receptor by Distinctive Pathways. PLoS One, 10(6) : e0129484.
[42] Gossmann J,Burkhardt R,Harder S,Lenz T,Sedlmeyer A,Klinkhardt U .2001 .Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptordependent pathway. Kidney Int, 60(1) : 83-6.
[43] Ishizaka N,Saito K,Noiri E,Sata M,Ikeda H,Ohno A .2005 .Administration of ANG II induces iron deposition and upregulation of TGF-beta1 mRNA in the rat liver. Am J Physiol Regul Integr Comp Physiol, 288(4) : R1063-70.
[44] Tajima S,Tsuchiya K,Horinouchi Y,Ishizawa K,Ikeda Y,Kihira Y .2010 .Effect of angiotensin II on iron-transporting protein expression and subsequent intracellular labile iron concentration in human glomerular endothelial cells. Hypertens Res, 33(7) : 713-21.
[45] Tajima S,Ikeda Y,Enomoto H,Imao M,Horinouchi Y,IzawaIshizawa Y .2015 .Angiotensin II alters the expression of duodenal iron transporters, hepatic hepcidin, and body iron distribution in mice. Eur J Nutr, 54(5) : 709-19.
[46] Rodgers KE,Xiong S,Steer R .2000 .Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells, 18(4) : 287-94.
[47] Shen XZ,Bernstein KE .2011 .The peptide network regulated by angiotensin converting enzyme (ACE) in hematopoiesis. Cell Cycle, 10(9) : 1363.
[48] Cao DY,Saito S,Veiras LC,Okwan-Duodu D,Bernstein EA,Giani JF .2020 .Role of angiotensin-converting enzyme in myeloid cell immune responses. Cell Mol Biol Lett, 25(1) : 1-12.
[49] Kim S,Zingler M,Harrison JK,Scott EW,Cogle CR,Luo D .2016 .Angiotensin II Regulation of Proliferation, Differentiation and Engraftment of Hematopoietic Stem Cells. Hypertension, 67(3) : 574.
[50] Lo  Pez-Farre A,Sa  Nchez De Miguel L,Ân MM,Jime Ânez A,Lopez-Bloya A,Go  Mez J .2001 .Angiotensin II AT1 receptor antagonists and platelet activation. Nephrol Dial Transplant, 16(Suppl 1) : 45-9.
[51] Montezano AC,Nguyen Dinh Cat A,Rios FJ,Touyz RM .2014 .Angiotensin II and vascular injury. Curr Hypertens Rep, 16(6) : 431.
[52] Ahmed GM,Abed MN,Alassaf FA .2023 .An overview of the effects of sodium-glucose co-transporter-2 inhibitors on haematological parameters in diabetic patients. Iraqi J Pharm, 20(1) : 65-71.
[53] Alicic RZ,Neumiller JJ,Johnson EJ,Dieter B,Tuttle KR .2019 .Sodium-Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease. Diabetes, 68(2) : 248-57.
[54] Shinozaki K,Ayajiki K,Nishio Y,Sugaya T,Kashiwagi A,Okamura T .2004 .Evidence for a causal role of the renin-angiotensin system in vascular dysfunction associated with insulin resistance. Hypertension, 43(2) : 255-62.
[55] Underwood PC,Adler GK .2013 .The Renin Angiotensin Aldosterone System and Insulin Resistance in Humans. Curr Hypertens Rep, 15(1) : 59.
[56] Alassaf FA,Jasim MHM,Alfahad M,Qazzaz ME,Abed MN,Thanoon IA .2021 .Effects of bee propolis on FBG, HbA1c and insulin resistance in healthy volunteers. Turk J Pharm Sci, 18(4) : 405-9.
[57] Peti-Peterdi J,Kang JJ,Toma I. .2008 .Activation of the renal reninangiotensin system in diabetes-new concepts. Nephrol Dial Transplant, 23(10) : 3047.
[58] Vlahakos DV,Marathias KP,Madias NE .2010 .The role of the reninangiotensin system in the regulation of erythropoiesis. Am J Kidney Dis, 56(3) : 558-65.
[59] Iriyama T,Wang W,Parchim NF,Song A,Blackwell SC,Sibai BM .2015 .Hypoxia-independent upregulation of placental hypoxia inducible factor-1α gene expression contributes to the pathogenesis of preeclampsia. Hypertenssion, 65(6) : 1307-15.
[60] Cole J,Ertoy D,Lin H,Sutliff RL,Ezan E,Guyene TT .2000 .Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting enzyme-deficient mice. J Clin Invest, 106(11) : 1391-8.
[61] Raptis AE,Bacharaki D,Mazioti M,Marathias KP,Markakis KP,Raptis SA .2012 .Anemia due to coadministration of reninangiotensin-system inhibitors and PPARγ agonists in uncomplicated diabetic patients. Exp Clin Endocrinol Diabetes, 120(7) : 416-9.
[62] Alzoubi B,Kharel A,Machhi R,Aziz F,Swanson KJ,Parajuli S .2021 .Post-transplant erythrocytosis after kidney transplantation: A review. World J Transplant, 11(6) : 220-30.
[63] Vlahakos DV,Marathias KP,Kosmas EN .2001 .Losartan reduces hematocrit in patients with chronic obstructive pulmonary disease and secondary erythrocytosis. Ann Intern Med, 134(5) : 426-7.
[64] Dunlay SM,Weston SA,Redfield MM,Killian JM,Roger VL .2008 .Anemia and heart failure: a community study. Am J Med, 121(8) : 726-32.
[65] Kamper AL,Nielsen OJ .1990 .Effect of enalapril on haemoglobin and serum erythropoietin in patients with chronic nephropathy. Scand J Clin Lab Invest, 50(6) : 611-8.
[66] Witte KKA,Desilva R,Chattopadhyay S,Ghosh J,Cleland JGF,Clark AL .2004 .Are hematinic deficiencies the cause of anemia in chronic heart failure. Am Heart J, 147(5) : 924-30.
[67] Nanas JN,Matsouka C,Karageorgopoulos D,Leonti A,Tsolakis E,Drakos SG .2006 .Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol, 48(12) : 2485-9.
[68] Macdougall IC,Cooper AC .2005 .Hyporesponsiveness to erythropoietic therapy due to chronic inflammation. Eur J Clin Invest, 35(Suppl 3) : 32-5.
[69] Iversen PO,Woldbaek PR,Tønnessen T,Christensen G .2002 .Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am J Physiol Regul Integr Comp Physiol, 282(1) : R166-72.
[70] Jankowska EA,Malyszko J,Ardehali H,Koc-Zorawska E,Banasiak W,Von Haehling S .2013 .Iron status in patients with chronic heart failure. Eur Heart J, 34(11) : 827-34.
[71] Chiang CK,Tanaka T,Inagi R,Fujita T,Nangaku M. .2011 .Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. Lab Invest, 91(11) : 1564-71.
[72] Huang JY,Hsu CW,Yang CW,Hung CC,Huang WH .2016 .Role of anuria in the relationship between indoxyl sulfate and anemia in peritoneal dialysis patients. Ther Clin Risk Manag, 12 : 1797-803.
[73] Bataille S,Pelletier M,Sallée M,Berland Y,McKay N,Duval A .2017 .Indole 3-acetic acid, indoxyl sulfate and paracresylsulfate do not influence anemia parameters in hemodialysis patients. BMC Nephrol, 18(1) : 251.
[74] Ezekowitz JA,McAlister FA,Armstrong PW .2003 .Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation, 107(2) : 223-5.
[75] Anand IS,Kuskowski MA,Rector TS,Florea VG,Glazer RD,Hester A .2005 .Anemia and change in haemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation, 112(8) : 1121-7.
[76] Go AS,Yang J,Ackerson LM,Lepper K,Robbins S,Massie BM .2006 .Haemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation, 113(23) : 2713-23.
[77] Mozaffarian D,Nye R,Levy WC .2003 .Anemia predicts mortality in severe heart failure: The prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol, 41(11) : 1933-9.
[78] Sîrbu O,Floria M,Dascalita P,Stoica A,Adascalitei P,Sorodoc V .2018 .Anemia in heart failure - from guidelines to controversies and challenges. Anatol J Cardiol, 20(1) : 52-9.
[79] Azizi M,Junot C,Ezan E,Ménard J .2001 .Angiotensin I-converting enzyme and metabolism of the haematological peptide Nacetyl-seryl-aspartyl-lysyl-proline. Clin Exp Pharmacol Physiol, 28(12) : 1066-9.
[80] Vlahakos DV,Marathias KP,Agroyannis B,Madias NE .2003 .Posttransplant erythrocytosis. Kidney Int, 63(4) : 1187-94.
[81] Salzberg DJ,Karadsheh FF,Haririan A,Reddivari V,Weir MR .2014 .Specific management of anemia and hypertension in renal transplant recipients: influence of renin-angiotensin system blockade. Am J Nephrol, 39(1) : 1-7.
[82] Vlahakos D V.,Tsioufis C,Manolis A,Filippatos G,Marathias KP,Papademetriou V .2019 .Inhibition of the renin-angiotensin system in the cardiorenal syndrome with anaemia: a doubleedged sword. J Hypertens, 37(11) : 2145-53.
[83] Drüeke TB,Locatelli F,Clyne N,Eckardt KU,Macdougall IC,Tsakiris D .2006 .Normalization of Haemoglobin Level in Patients with Chronic Kidney Disease and Anemia. N Engl J Med, 20(16) : 2071-84.
[84] Swedberg K,Young JB,Anand IS,Cheng S,Desai AS,Diaz R .2013 .Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med, 368(13) : 1210-9.
[85] Jankowska EA,Tkaczyszyn M,Suchocki T,Drozd M,von Haehling S,Doehner W .2016 .Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail, 18(7) : 786-95.
[86] Wright JT,Williamson JD,Whelton PK,Snyder JK,Sink KM,Rocco MV .2015 .A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med, 373(22) : 2103-16.
[87] Cheung AK,Rahman M,Reboussin DM,Craven TE,Greene T,Kimmel PL .2017 .Effects of Intensive BP Control in CKD. J Am Soc Nephrol, 28(9) : 2812-23.
[88] Vardeny O,Claggett B,Packer M,Zile MR,Rouleau J,Swedberg K .2016 .Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail, 18(10) : 1228-34.
[89] Yamada S,Inaba M .2021 .Potassium Metabolism and Management in Patients with CKD. Nutrients, 13(6) : .
[90] Bakris GL,Weir MR .2000 .Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?. Arch Intern Med, 160(5) : 685-93.
[91] Burnier M.,Renin-Angiotensin System M. .2020 .. Advanced Kidney Disease: Stop or Continue? Kidney Med, 2(3) : 231-4.